Pipeline

In order to demonstrate the diversity of the AMR-dedicated SMEs’ pipeline in Europe, the BEAM Alliance has collated its members’ technological assets into a comprehensive portfolio. While its size is already impressive, the proposed categorization approach is further revealing the high level of innovativeness that is being deployed, both at clinical and preclinical stages.

                                 

Pipeline Rx

Click on column headers to sort the table

memberproductbictypetargetinnovation
criteria
development
stage
MaaT PharmaMaaT0333cOtherBroad Gram +/-
Priority Pathogen *
Acute Myeloid Leukemia
New Class
New Target
New MoA
Phase I
MaaT PharmaMaaT0133cOtherBroad Gram +/-
Priority Pathogen *
GvHD
New Class
New Target
New MoA
Phase II
MaaT PharmaMaaT0125bOtherBroad Gram +/-
 
Acute Myeloid Leukemia
New Class
New Target
New MoA
Phase II
Basilea Pharmaceutica International Ltd.undisclosed3aNMEGram -
Priority Pathogen *
Serious infections in hospitalized patients
New ClassLead opt
Basilea Pharmaceutica International Ltd.Non beta-lactam PBP inhibitor3aNMEGram -
Priority Pathogen *
Serious infections in hospitalized patients
New ClassLead opt
Pherecydes PharmaPP11513aPhagePrecise Pathogen ID
Priority Pathogen *
MDR infections to Escherichia coli
New Class
New MoA
Pre-clinical
Pherecydes PharmaPP10023aPhagePrecise Pathogen ID
Priority Pathogen *
MDR infections to Escherichia coli
New Class
New MoA
Pre-clinical
Pherecydes PharmaPP9703aPhagePrecise Pathogen ID
Priority Pathogen *
MDR infections to Escherichia coli
New Class
New MoA
Pre-clinical
Pherecydes PharmaPP9543aPhagePrecise Pathogen ID
Priority Pathogen *
MDR infections to Escherichia coli
New Class
New MoA
Pre-clinical
Pherecydes PharmaPP8143aPhagePrecise Pathogen ID
Priority Pathogen *
MDR infections to Escherichia coli
New Class
New MoA
Pre-clinical
Pherecydes PharmaPP7003aPhagePrecise Pathogen ID
Priority Pathogen *
MDR infections to Escherichia coli
New Class
New MoA
Pre-clinical
Assuré Medical LimitedSol-UTI1bOtherGram -
Priority Pathogen *
Recurrent Urinary Tract Infection (rUTI)
New Target
New MoA
Pre-clinical
BioVersys AGBV1003aNMEGram -
Priority Pathogen *
A. baumannii (HAP,VAP, BSI)
New MoAPre-clinical
Madam Therapeutics BVP103aProtein/PeptideBroad Gram +/-
Priority Pathogen *
Veterinary Diseases (companion animals and lifestock)
New Class
New Target
New MoA
Pre-clinical
Destiny Pharma plcDPD-2073aNMEGram +
Priority Pathogen *
MDR bacterial eye infections
New Class
New Target
New MoA
Pre-clinical
AlphanososW9P1543eOtherPrecise Pathogen ID
Priority Pathogen *
Tuberculosis, Buruli Ulcer
New Class
New Target
New MoA
Lead opt
ABAC therapeuticsABAC-40,2443aNMEPrecise Pathogen ID
Priority Pathogen *
Infections by MDR/XDR Staph aureus
New Class
New Target
New MoA
Lead opt
ABAC therapeuticsABAC-401053aNMEGram -
Priority Pathogen *
Infections by MDR/XDR A baumannii, including ColistinR and CarbapenemR
New Class
New Target
New MoA
Lead opt
ANTABIO S.A.SANT_SBLi3dNMEBroad Gram -
Priority Pathogen *
Hospital-acquired infections caused by carbapenem-resistant Enterobacteriaceae (CRE) and Acinetobacter [cUTI, cIAI, Nosocomial Pneumonia]
New MoALead opt
VibioSphenSativa3bNME 
 
Pulmonary infection, UTI
Pre-clinical
VAXDYNVXD-0021aVaccinePrecise Pathogen ID
Priority Pathogen *
Hospital/community acquired untreatable or difficult-to-treat infections, caused by Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii
New Class
New Target
New MoA
Lead opt
VAXDYNVXD-0033cAntibodyPrecise Pathogen ID
Priority Pathogen *
Hospital/community acquired untreatable or difficult-to-treat infections, caused by Acinetobacter baumannii
New Class
New Target
New MoA
Lead opt
VAXDYNVXD-0011aVaccinePrecise Pathogen ID
Priority Pathogen *
Hospital/community acquired untreatable or difficult-to-treat infections, caused by Acinetobacter baumannii
New Class
New Target
New MoA
Pre-clinical
Summit Therapeutics plcSMT0265713aNMEGram -
Priority Pathogen *
Gonorrhoea infection
New Class
New Target
New MoA
Pre-clinical
Summit Therapeutics plcRidinilazole3aNMEGram +
Priority Pathogen *
Clostridium difficile infection
New Class
New Target
New MoA
Phase III
SetLance srlSET-M333aProtein/PeptideBroad Gram +/-
Priority Pathogen *
Sepsis, pneumonia and skin infections
Pre-clinical
QureTech Bio ABTIB3aNMEPrecise Pathogen ID
 
Trachoma, Chlamydia eye infection
New Class
New Target
New MoA
Lead opt
QureTech Bio ABGmP3dNMEGram +
Priority Pathogen *
VRE and MRSA
New Class
New Target
New MoA
Lead opt
QureTech Bio ABCIB3aNMEPrecise Pathogen ID
Priority Pathogen *
Genital Chlamydia infection
New Class
New Target
New MoA
Lead opt
QureTech Bio ABMTI3dNMEPrecise Pathogen ID
Priority Pathogen *
MDR Tuberculosis
New Class
New Target
New MoA
Pre-clinical
PureIMS BVTobramycin Cyclops™3aOtherGram -
Priority Pathogen *
Cystic Fibrosis
Phase I
PureIMS BVIsoniazid Cyclops™3aOtherBroad Gram +/-
Priority Pathogen *
Tuberculosis
IND/CTA ready
PureIMS BVLinezolid Cyclops™3aOtherBroad Gram +/-
Priority Pathogen *
Tuberculosis
IND/CTA ready
PureIMS BVAmikacin Cyclops™3aOtherGram -
Priority Pathogen *
Multidrug-resistant tuberculosis (MDR-TB)
IND/CTA ready
PureIMS BVColistin Cyclops™3aProtein/PeptideGram -
Priority Pathogen *
Cystic Fibrosis
Marketed
Polyphor LtdMurepavadin (inhaled)3aProtein/PeptideGram -
Priority Pathogen *
Cystic Fibrosis; Bronchiectasis
New Class
New Target
New MoA
Lead opt
Polyphor LtdOMPTA3aProtein/PeptideGram -
Priority Pathogen *
HAP, VAP, UTI, IAI, other
New Class
New Target
New MoA
Lead opt
Polyphor LtdMurepavadin3aProtein/PeptideGram -
Priority Pathogen *
HAP, VAP
New Class
New Target
New MoA
Phase III
Phico Therapeutics LtdSASPject™ PT43aOtherPrecise Pathogen ID
Priority Pathogen *
Serious Klebsiella Pneumoniae infections where treatment options are limited
New Target
New MoA
Pre-clinical
Phico Therapeutics LtdSASPject™ PT53aOtherPrecise Pathogen ID
Priority Pathogen *
Serious E.coli infections where treatment options are limited
New Target
New MoA
Pre-clinical
Phico Therapeutics LtdSASPject™ PT3.83aOtherPrecise Pathogen ID
Priority Pathogen *
Serious Pseudomonas Aeruginosa infections where treatment options are limited
New Target
New MoA
Pre-clinical
Pherecydes PharmaPN17773aPhagePrecise Pathogen ID
Priority Pathogen *
MDR infections to Pseudomonas aeruginosa
New Class
New MoA
Pre-clinical
Pherecydes PharmaPN17923aPhagePrecise Pathogen ID
Priority Pathogen *
MDR infections to Pseudomonas aeruginosa
New Class
New MoA
Pre-clinical
Pherecydes PharmaPN17973aPhagePrecise Pathogen ID
Priority Pathogen *
MDR infections to Pseudomonas aeruginosa
New Class
New MoA
Pre-clinical
Pherecydes PharmaPN14933aPhagePrecise Pathogen ID
Priority Pathogen *
MDR infections to Staphylococcus aureus
New Class
New MoA
Pre-clinical
Pherecydes PharmaPN18153aPhagePrecise Pathogen ID
Priority Pathogen *
MDR infections to Staphylococcus aureus
New Class
New MoA
Pre-clinical
Pherecydes PharmaPN19573aPhagePrecise Pathogen ID
Priority Pathogen *
MDR infections to Staphylococcus aureus
New Class
New MoA
Pre-clinical
Pherecydes PharmaPN14503aPhagePrecise Pathogen ID
Priority Pathogen *
MDR infections to Pseudomonas aeruginosa
New Class
New MoA
Pre-clinical
PhagoMed Biopharma GmbHPhM3983aPhagePrecise Pathogen ID
Priority Pathogen *
Periprosthetic Joint Infections
New Class
New MoA
Lead opt
PhagoMed Biopharma GmbHPhM7543aPhagePrecise Pathogen ID
Priority Pathogen *
Urinary Tract Infections
New Class
New MoA
Lead opt
Omnix MedicalOMN63aProtein/PeptideGram -
Priority Pathogen *
A. baumannii induced Bacteremia or HABP or VABP
New Class
New MoA
Lead opt
NovaBiotics LtdNovamycin®3aProtein/PeptideNon Bacterial Target
Priority Pathogen *
Invasive Fungal Disease, mucocutaneous fungal infections
New Class
New Target
New MoA
Pre-clinical
NovaBiotics LtdNylexa™3dOtherBroad Gram +/-
Priority Pathogen *
Resistance breaker
New Class
New Target
New MoA
Pre-clinical
NovaBiotics LtdNovarifyn®3aProtein/PeptideBroad Gram +/-
Priority Pathogen *
Gram negative and Gram negative reistant/MDR infections (ESKAPE), some Gram positive coverage
New Class
New Target
New MoA
Pre-clinical
NovaBiotics LtdLuminaderm®1bProtein/PeptideBroad Gram +/-
Priority Pathogen *
MRSA
New Class
New Target
New MoA
Pre-clinical
NovaBiotics LtdLynovex® inhaled1aOtherBroad Gram +/-
Priority Pathogen *
Cystic Fibrosis
New Class
New Target
New MoA
IND/CTA ready
NovaBiotics LtdNovexatin®3aProtein/PeptideNon Bacterial Target
Priority Pathogen *
Onychomycosis
New Class
New Target
New MoA
Phase II
NovaBiotics LtdLynovex® oral3bOtherBroad Gram +/-
Priority Pathogen *
Cystic Fibrosis
New Class
New Target
New MoA
Phase II
NosopharmNOSO-A43aNMEBroad Gram +/-
Priority Pathogen *
P. aeruginosa infections
New Class
New Target
New MoA
Discovery
NosopharmNOSO-5023aNMEGram -
Priority Pathogen *
MDR Enterobacteriaceae infections
New Class
New Target
New MoA
Pre-clinical
Northern Antibiotics Oy (Ltd)NAB8153aProtein/PeptideGram -
Priority Pathogen *
cUTI caused by MDR Gram-negatives
Pre-clinical
Northern Antibiotics Oy (Ltd)NAB7393aProtein/PeptideGram -
Priority Pathogen *
cUTI caused by MDR Gram-negatives
Pre-clinical
Neem Biotech LtdNX-AS-9115aNMEBroad Gram +/-
Priority Pathogen *
Treatment of infected wounds (P. aeruginosa, S. aureus), inlcuding those with a biofilm presence.
New Class
New MoA
Pre-clinical
Neem Biotech LtdNX-AS-4015aNMEGram -
Priority Pathogen *
Treatment of chronic P. aeruginosa lung infection in people with cystic fibrosis
New Class
New MoA
Pre-clinical
Nabriva Therapeutics plcLefamulin3aNMEBroad Gram +/-
Priority Pathogen *
ABSSSI
New Class
New Target
New MoA
Phase II
Nabriva Therapeutics plcLefamulin3aNMEBroad Gram +/-
Priority Pathogen *
STIs, HABP/VABP, Osteomyelitis, Prosthetic Joint Infections
New Class
New Target
New MoA
Pre-clinical
Nabriva Therapeutics plcLefamulin3aNMEBroad Gram +/-
Priority Pathogen *
Pediatric Indications
New Class
New Target
New MoA
Phase I
Nabriva Therapeutics plcLefamulin3aNMEBroad Gram +/-
Priority Pathogen *
CABP (community-acquired bacterial pneumonia)
New Class
New Target
New MoA
Phase III
Mutabilis SASDabocins3aOtherGram -
Priority Pathogen *
Against multi-drug resistant enterobacteriaceae (CRE) and/or P. aeruginosa
Lead opt
Mutabilis SASPO3dOtherGram -
Priority Pathogen *
Against ESBL/OXA-48/KPC expressing Enterobacteriaceae
Pre-clinical
Mutabilis SASdlta inhibitor1bOtherGram +
Priority Pathogen *
Preventive treatment for patient at risk of nosocomial infection by Staphylococci, Streptococci and Enterococci
New Class
New Target
Lead opt
Mutabilis SASgmha inhibitor1bOtherGram -
Priority Pathogen *
Preventive treatment for patient at risk of nosocomial infection by Enterobacteriaceae
Lead opt
Motif Bio plcIclaprim3aNMEGram +
Priority Pathogen *
Staphylococcus aureus Lung Infections Among Cystic Fibrosis Patients
Pre-clinical
Motif Bio plcIclaprim3aNMEGram +
Priority Pathogen *
ABSSSI
Phase III
Motif Bio plcIclaprim3aNMEGram +
Priority Pathogen *
HABP/VABP
Phase III
Madam Therapeutics BVSAAP1483aProtein/PeptideBroad Gram +/-
Priority Pathogen *
Diabetic foot ulcers, burns and MRSA carriership
New Class
New Target
New MoA
Pre-clinical
MaaT PharmaMaaT0115aOtherBroad Gram +/-
 
Acute Myeloid Leukemia
New Class
New Target
New MoA
Phase II
MaaT PharmaMaaT0311bOtherBroad Gram +/-
 
Bone and Joint Infectious
New Class
New Target
New MoA
Phase I
IMMUNETHEP, SAPNmAb 13cAntibodyBroad Gram +/-
Priority Pathogen *
Intensive Care Units / Hospital Acquired infections
New Class
New Target
New MoA
Lead opt
IMMUNETHEP, SAcPNV1aVaccineBroad Gram +/-
Priority Pathogen *
Preventive
New Class
New Target
Pre-clinical
Hypharm GmbHHY-1331bPhageGram +
Priority Pathogen *
Nasal colonization with MRSA
New Class
New Target
New MoA
Pre-clinical
Helperby Therapeutics LtdHY-0013dOtherGram -
Priority Pathogen *
Urinary Tract Infections
New Class
New Target
New MoA
Phase I
Helperby Therapeutics LtdHY-0023dOtherGram -
Priority Pathogen *
Intra-Abdominal Infections
New Class
New Target
New MoA
Phase I
Helperby Therapeutics LtdHY-0041bOtherGram +
Priority Pathogen *
Nasal MRSA decolonisation
New Class
New Target
New MoA
Phase II
Helperby Therapeutics LtdHY-0053dOtherGram +
Priority Pathogen *
Skin & Soft Tissue MRSA
New Class
New Target
New MoA
Phase II
Eligo BioscienceEB0041bOtherPrecise Pathogen ID
Priority Pathogen *
Multi-drug resistant Enterobacteriaceae
New Class
New MoA
Pre-clinical
Destiny Pharma plcXF-733dNMEBroad Gram +/-
Priority Pathogen *
Hospital pneumonia/ventilator-associated pneumonia (VAP)
New Class
New Target
New MoA
Pre-clinical
Destiny Pharma plcXF-703aNMEBroad Gram +/-
Priority Pathogen *
Dermal burn wound infections
New Class
New Target
New MoA
Phase I
Destiny Pharma plcXF-701bNMEBroad Gram +/-
Priority Pathogen *
Bacterial biofilm-infections
New Class
New Target
New MoA
Pre-clinical
Destiny Pharma plcXF-731bNMEBroad Gram +/-
Priority Pathogen *
Post-surgical nasal decolonisation
New Class
New Target
New MoA
Phase II
DEINOVEDNV38373aNMEBroad Gram +/-
Priority Pathogen *
C.difficile gastrointestinal infections
New Class
New MoA
Phase I
Debiopharm InternationalDebio 14533aNMEGram -
Priority Pathogen *
N. gonorrhoeae
New Class
New Target
New MoA
Discovery
Debiopharm InternationalAfabicin (Debio 1450)3aNMEPrecise Pathogen ID
Priority Pathogen *
ABSSSI, Bone & Joint Infections (BJIs)
New Class
New Target
New MoA
Phase II
Combioxin SACAL023bOtherBroad Gram +/-
Priority Pathogen *
Severe infections
New Class
New Target
New MoA
Phase II
Centauri Therapeutics LtdABX013cOtherGram -
Priority Pathogen *
Broad spectrum Gram negative, including clinically-relevant strains of Enterobacteriaceae, P. aeruginosa, and A. baumannii
New Class
New Target
New MoA
Pre-clinical
Centauri Therapeutics LtdABX023cOtherPrecise Pathogen ID
Priority Pathogen *
Pseudomonas Aeruginosa specific Inhibitor
New Class
New Target
New MoA
Pre-clinical
BioVersys AGBV2004aNMEGram +
Priority Pathogen *
Anti-toxin for Staphylococcus aureus
New Class
New Target
New MoA
Lead opt
BioVersys AGBV4003bNMEGram -
Priority Pathogen *
Anti Virulence in Gram negative bacteria, Enterobacteriaceae and A. baumannii
New Class
New Target
New MoA
Lead opt
BioVersys AGBVL-GSK0X83dNMEPrecise Pathogen ID
Priority Pathogen *
Adjuvant reversing resistance and potentiating Ethionamide activity in Tuberculosis
New Class
New Target
New MoA
Pre-clinical
BioFilm PharmaBFP0023eNMEBroad Gram +/-
Priority Pathogen *
Staphylococcus aureus, Pseudomonas aeruginosa Systemic – Cystic Fibrosis
New Target
New MoA
Lead opt
BioFilm PharmaBFP1013eNMEGram +
Priority Pathogen *
Staphylococcus aureus Local - Diabetic Foot Ulcer, Joint & Bone Infections
New Target
New MoA
Lead opt
BioFilm PharmaBFP1023eNMEBroad Gram +/-
Priority Pathogen *
Staphylococcus aureus, Pseudomonas aeruginosa Systemic – Cystic Fibrosis
New Class
New Target
New MoA
Lead opt
BioFilm PharmaBFP0013eNMEGram +
Priority Pathogen *
Staphylococcus aureus Local - Diabetic Foot Ulcer, Joint & Bone Infections
New Class
New Target
New MoA
Lead opt
Basilea Pharmaceutica International Ltd.Ceftobiprole3aNMEBroad Gram +/-
Priority Pathogen *
Acute bacterial skin and skin structure infections, Staphylococcus aureus bacteremia
Phase III
Basilea Pharmaceutica International Ltd.Ceftobiprole3aNMEBroad Gram +/-
Priority Pathogen *
Community- and hospital-acquired pneumonia (excluding ventilator-associated pneumonia)
Marketed
ANTABIO S.A.SANT_Pei3cNMEPrecise Pathogen ID
Priority Pathogen *
Pseudomonas infections in Cystic Fibrosis patients
New Class
New Target
New MoA
Lead opt
ANTABIO S.A.SANT26813dNMEGram -
Priority Pathogen *
Hospital-acquired infections caused by carbapenem-resistant Enterobacteriaceae (CRE) [cUTI, cIAI, Nosocomial Pneumonia]
New Class
New Target
New MoA
Pre-clinical
AlphanososW16P05763eOtherBroad Gram +/-
Priority Pathogen *
A. baumannii, P. aeruginosa, MRSA,N. gonorrhoeae, M. tuberculosis - Infectious skin conditions (eczema, acne, sporiasis, ...), difficult wounds
New Class
New Target
New MoA
Pre-clinical
ALLECRA THERAPEUTICScefepime/AAI1013dNMEBroad Gram +/-
Priority Pathogen *
cUTI, cIAI, HAP
Phase II
AlaxiaALX-0093aOtherBroad Gram +/-
Priority Pathogen *
Cystic Fibrosis
New Class
New Target
New MoA
Phase I
AktheliaHO53/HO56 ADP3cNMEBroad Gram +/-
Priority Pathogen *
Multidrug resistant lung infections including nosocomial infections (K. pneumoniae)
New Class
New Target
New MoA
Lead opt
AiCuris Anti-infective Cures GmbHAIC4993aNMEGram -
Priority Pathogen *
Gram-negative resistance breaker
New ClassPhase I
AGILeBiotics B.V.ABX-3953aNMEGram -
Priority Pathogen *
Hospital-treated MDR Gram-negative infections
Lead opt
AGILeBiotics B.V.ABX-6053aNMEGram -
Priority Pathogen *
Hospital-treated MDR Gram-negative infections
Lead opt
ABAC therapeuticsABAC-39,8773aNMEGram -
Priority Pathogen *
Infections by MDR/XDR A baumannii, including ColistinR and CarbapenemR
New Class
New Target
New MoA
Pre-clinical
Da VolterraDAV1214bOtherBroad Gram +/-
Priority Pathogen *
Prevention of gut microbiota antibiotic-dysbiosis and emergence of resistance to β-lactam antibiotics, including carbapenems
New Class
New Target
New MoA
Lead opt
Da VolterraDAV1324bOtherBroad Gram +/-
Priority Pathogen *
Prevention of C.difficile infections
New Class
New Target
New MoA
Phase II
PreviousPage 1/12show allNext

*Priority pathogens have been listed by WHO and CDC

The displayed information are not necessarily reflecting the official current position of each BEAM members; please refer to each company’s website for updated information, or contact them directly.

Pipeline Dx

Click on column headers to sort the table

memberkit/testtargeted resultpathogens & indicationslab workflowdevelopment stage
MilliDrop Instrument SASMDI-MICAST PhenotypingIncl. Priority Pathogens
Escherichia coli - Enterobacter Pseudomonas - Acinetobacter
Standard MIC determination for multi-resistant strains and new therapeutic strategies
From isolated colony
Microfluidic liquid handling
<8h
Feasibility Phase
MilliDrop Instrument SASMDI-SepsisID/AST combinedIncl. Priority Pathogens
Escherichia coli - Klebsiella - Enterobacter - Proteus - Pseudomonas - Haemophilus - Acinetobacter - Staphylococcus - Streptococcus - Candida
Sepsis
From whole blood
Microfluidic liquid handling
<24h
Feasibility Phase
Nanosynex LtdNanosyAST Phenotyping 
 
From isolated colony
Microfluidic chip/reader
<4h
Feasibility Phase
FASTinov SAFAST panel Gram+AST PhenotypingIncl. Priority Pathogens
S. aureus/epidermidis, E. faecalis / faecium / casseliflavus / gallinarum
From positive blood culture
Flow cytometer
<2h
Clinical Validation EU and/or US
FASTinov SAFAST panel Gram-AST PhenotypingIncl. Priority Pathogens
E. coli, K. pneumoniae, E. cloacae/aerogenes, P. aeruginosa, A. baumanii, S. marcescens, P. rettgeri
From positive blood culture
Flow cytometer
<2h
Clinical Validation EU and/or US
Debiopharm InternationalGenePOC™ Strep A, C/G testPathogen ID 
Detection of Group A, C and G β-hemolytic Streptococcus
From Swab
PCR/qPCR
<2h
Clinical Validation EU and/or US
Debiopharm InternationalGenePOC™ CARBA testAMR Gene IDIncl. Priority Pathogens
Detection of Carbapenemase Producing Organisms (CPOs)
From Swab
PCR/qPCR
<2h
Clinical Validation EU and/or US
Debiopharm InternationalGenePOC™ GBS LB testPathogen ID 
Detection of Group B Streptococcus (GBS) from Lim Broth samples
Other sample type
PCR/qPCR
<2h
CE-IVD and/or FDA 510k
Debiopharm InternationalGenePOC™ GBS DS testPathogen ID 
Detection of Group B Streptococcus (GBS) from direct vaginal/rectal swab
From Swab
PCR/qPCR
<2h
CE-IVD and/or FDA 510k
Debiopharm InternationalGenePOC™ CDiff testPathogen IDIncl. Priority Pathogens
Toxin B gene of C. difficile
From Stool
PCR/qPCR
<2h
CE-IVD and/or FDA 510k
BioFilm PharmaAntiBiofilmogram Urinary CareAST PhenotypingIncl. Priority Pathogens
E. coli
Urinary Tract Infections, Catheter Associated Urinary Tract Infections
From isolated colony
Microplate-reader
<4h
Development Phase
BioFilm PharmaAntiBiofilmogram Lung CareAST PhenotypingIncl. Priority Pathogens
Staphylococcus aureus
Cystic Fibrosis
From isolated colony
Microplate-reader
<4h
Prototype in Lab
BioFilm PharmaAntiBiofilmogram Lung CareAST PhenotypingIncl. Priority Pathogens
Pseudomonas aeruginosa
Cystic Fibrosis
From isolated colony
Microplate-reader
<4h
Prototype in Lab
BioFilm PharmaAntiBiofilmogram Wound CareAST PhenotypingIncl. Priority Pathogens
Staphylococcus aureus
Diabetic Foot Ulcer, Joint & Bone Infections
From isolated colony
Microplate-reader
<4h
Clinical Validation EU and/or US
MeMed Diagnostics Ltd.MeMed BV™Viral vs Bacterial 
 
Point-of-need discrimination of the viral/bacterial nature of an infection
From serum/plasma
 
<30 minutes
Clinical Validation EU and/or US
PreviousPage 1/2show allNext

The displayed information are not necessarily reflecting the official current position of each BEAM members; please refer to each company’s website for updated information, or contact them directly.